Share this story:

TAAT Provides Update on Status of Audited Financial Statements

TAAT Global Alternatives Inc.

LAS VEGAS and VANCOUVER – TheNewswire - May 15, 2024 – TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTC: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is providing this update pursuant to the management cease trade order granted on February 29, 2024 by the British Columbia Securities Commission ("BCSC") under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On February 29, 2024, the Company announced that there would be a delay in the filing of its financial statements and accompanying management’s discussion and analysis for the fiscal year ended October 31, 2023 (the "Annual Filings") beyond the period prescribed under applicable Canadian securities laws (the "Default Announcement"). On May 14, 2024, the BCSC has issued a cease trade order under Multilateral Instrument 11-103 – Failure-to-File Cease Trade Orders in Multiple Jurisdictions (the "FFCTO") against the Company due to the continued delay of the Annual Filings in accordance with the regulations.


The Company advises that the Annual Filings have been delayed due to additional audit procedures, added complexities of auditing certain transactions during the financial year and the auditor has required additional time for partner and consultant review as part of those enhanced measures. The Company is working diligently with its auditors to complete the audit and will make the required filings as soon as possible. The auditors have advised the Company that they except to be able to complete their review and release their audit report in approximatley one weeks time.


The Company confirms that there is no material information concerning the affairs of the Company that has not been generally disclosed. The Company will provide further updates on timing if it anticipates any additional delays.


On behalf of the Board of Directors of the Company,




“Michael Saxon”


Michael Saxon, CEO and Director


For further information, please contact:


TAAT® Investor Relations

1-833-TAAT-USA (1-833-822-8872)




About TAAT® Global Alternatives Inc.


TAAT® is a vertically integrated consumer product and distribution company, generating more than CAD $90 million in overall gross revenue annually. TAAT® is strategically expanding its product categories including tobacco and reduced-risk alternatives, hemp, kratom, and other emerging CPG segments. TAAT® has facilities to include a processing plant in Nevada as well as a distribution centre in Canton, Ohio, leveraging existing retail shelf space and pipelines into national wholesale channels.


For more information, please visit


Forward-Looking Statements


Certain information contained herein may constitute "forward-looking information" or "forward-looking statements" under Canadian securities legislation. Generally, forward-looking information can be identified by words such as "pro forma", "plans", "expects", "may", "should", "could", "will", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or variations including negative variations thereof of such words and phrases that refer to certain actions, events or results that may, occur or be taken or achieved. Such forward-looking statements, including but not limited to statements relating to the expected development and operations of the Company, statements concerning the timing, review, completion and filing of the Annual Filings as well as the duration of the FFCTO, involve risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Corporation will not update any forward-looking statements or forward-looking information included herein, except as required by applicable securities laws.


The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.


This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.


Statement Regarding Third-Party Investor Relations Firms


Disclosures relating to investor relations firms retained by TAAT® Global Alternatives Inc. can be found under the Company's profile on